Drugs / Allogeneic Human Mesenchymal Stem Cells
Allogeneic Human Mesenchymal Stem Cells
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01983709 | Oct 2013 → Jun 2017 | prostate cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03265808 | Mar 2018 → Jul 2025 | alcohol dependence, major depressive disorder | Ihsan M Salloum, MD, MPH | Completed | No outcome recorded |
| Phase 1/2 | NCT02065245 | Mar 2014 → Oct 2019 | — | Longeveron Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04476901 | May 2021 → Apr 2027 expected | dilated cardiomyopathy | Joshua M Hare | Recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT05522569 | — | ischemic stroke | University of Miami | No longer available | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2017-10-17 | Longeveron Inc. | Results Longeveron Pioneering Development of Stem Cell Therapies for Aging Frailty longeveron.com ↗
The results of both studies were published in the October 12 issue of the Journals of Gerontology. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-10-17 | Longeveron Inc. | Longeveron Pioneering Development of Stem Cell Therapies for Aging Frailty longeveron.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic Human Mesenchymal Stem Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01983709 ↗ |
| Known as | allo-hMSCs | “allo-hMSCs, 16-20 million cells/ml delivered at a dose of 0.5 ml/ injection x 10 injections for a total of 80-100 million allo-hMSCs or a single administration of intravenous...” NCT04476901 ↗3“Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion” NCT02065245 ↗ “allogeneic human mesenchymal stem cells (allo-hMSCs)” NCT03265808 ↗ “Allogeneic human mesenchymal stem cells (Allo-hMSCs)” NCT05522569 ↗ |
| Known as | hMSCs | “allogeneic human mesenchymal stem cells (hMSCs)” NCT04476901 ↗ |
| Modality | Cell therapy | “systemically infused allogeneic bone marrow derived mesenchymal stem cells” NCT01983709 ↗ |
| Route | Intravenous | “a maximum dose of 1 x 10\^8 total cells IV” NCT01983709 ↗ |